PMID- 17207889
OWN - NLM
STAT- MEDLINE
DCOM- 20070605
LR  - 20220408
IS  - 0169-5002 (Print)
IS  - 0169-5002 (Linking)
VI  - 56
IP  - 1
DP  - 2007 Apr
TI  - Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in 
      nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
PG  - 43-50
AB  - BACKGROUND: Urokinase plasminogen activator (uPA) and plasminogen activator 
      inhibitor type-1 (PAI-1) have previously been suggested as prognostic markers in 
      nonsmall-cell lung carcinomas (NSCLC). We investigate whether uPA and PAI-1 are 
      prognostic markers in NSCLC and whether they are related to angiogenesis. 
      MATERIALS AND METHODS: Frozen tumour tissue from surgical specimens from 118 
      previously untreated patients diagnosed with NSCLC in the period 1984-1991 were 
      investigated. All patients were treated with surgery, and no chemo- or 
      radiotherapy was given. UPA and PAI-1 levels were assessed using a sandwich ELISA 
      method. RESULTS: Both uPA and PAI-1 were independent of classical 
      histopathological parameters as well as of microvessel density and vascular 
      pattern. Using death within the first 5 years as endpoint, neither of the factors 
      were prognostic markers in univariate analysis, however, significantly higher 
      levels of uPA and PAI-1 were seen in tumours with an angiogenic vascular pattern. 
      In multivariate analysis, high disease stage (P<0.0001), adenocarcinoma 
      (P=0.007), old age (P=0.02), and presence of an angiogenic pattern (P=0.05) were 
      identified as independent markers of death within 5 years. CONCLUSIONS: The 
      present study investigated the prognostic role of the protein levels of uPA and 
      PAI-1 in 118 tumour specimens from patients diagnosed with NSCLC. Neither of the 
      factors were identified as prognostic markers when evaluated with survival as 
      endpoint. However, in tumours previously identified as non-angiogenic we found 
      significantly lower contents of both uPA and PAI-1 as compared to angiogenic 
      tumours, thus we hypothesize that uPA and PAI-1 stimulate angiogenesis in NSCLC.
FAU - Offersen, Birgitte Vrou
AU  - Offersen BV
AD  - Department of Experimental Clinical Oncology, Aarhus University Hospital, 
      Norrebrogade 44, Bld. 5, DK-8000 Aarhus C, Denmark. bvo@oncology.dk
FAU - Pfeiffer, Per
AU  - Pfeiffer P
FAU - Andreasen, Peter
AU  - Andreasen P
FAU - Overgaard, Jens
AU  - Overgaard J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070117
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Plasminogen Activator Inhibitor 1)
RN  - EC 3.4.21.73 (Urokinase-Type Plasminogen Activator)
SB  - IM
MH  - Aged
MH  - Biomarkers, Tumor/*analysis
MH  - Carcinoma, Non-Small-Cell Lung/*chemistry/pathology
MH  - Chi-Square Distribution
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*chemistry/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Neovascularization, Pathologic/pathology
MH  - Plasminogen Activator Inhibitor 1/*analysis
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Survival Rate
MH  - Urokinase-Type Plasminogen Activator/*analysis
EDAT- 2007/01/09 09:00
MHDA- 2007/06/06 09:00
CRDT- 2007/01/09 09:00
PHST- 2006/08/15 00:00 [received]
PHST- 2006/11/05 00:00 [revised]
PHST- 2006/11/27 00:00 [accepted]
PHST- 2007/01/09 09:00 [pubmed]
PHST- 2007/06/06 09:00 [medline]
PHST- 2007/01/09 09:00 [entrez]
AID - S0169-5002(06)00622-2 [pii]
AID - 10.1016/j.lungcan.2006.11.018 [doi]
PST - ppublish
SO  - Lung Cancer. 2007 Apr;56(1):43-50. doi: 10.1016/j.lungcan.2006.11.018. Epub 2007 
      Jan 17.